New TB vaccine granted orphan drug status.

New TB vaccine granted orphan drug status.

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Lang, T, Hill, A, Mcshane, H, Shah, R, Towse, A, Pritchard, C, Garau, M
التنسيق:	Journal article
اللغة:	English
منشور في:	2005

مواد مشابهة

Towards new TB vaccines
حسب: Brazier, B, وآخرون
منشور في: (2020)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
حسب: Kalipso Chalkidou, وآخرون
منشور في: (2020-04-01)

TB vaccines in clinical development
حسب: Ginsberg, A, وآخرون
منشور في: (2016)

TB vaccines in clinical development
حسب: Ginsburg, A, وآخرون
منشور في: (2016)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
حسب: Mcshane, H
منشور في: (2008)

Need for more TB vaccine field sites.
حسب: Mcshane, H
منشور في: (2009)

Development of Orphan Vaccines: An Industry Perspective
حسب: Jean Lang, وآخرون
منشور في: (1999-12-01)

TB vaccines in clinical development
حسب: Ginsberg, AM, وآخرون
منشور في: (2016)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
حسب: Whelan, K, وآخرون
منشور في: (2009)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
حسب: Minassian, A, وآخرون
منشور في: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
حسب: Owiafe, P, وآخرون
منشور في: (2012)

Implementation status of pharmacological studies in the development of orphan drugs
حسب: Saki Yokoshiki, وآخرون
منشور في: (2024-01-01)

TB vaccine development: where are we and why is it so difficult?
حسب: Wilkie, M, وآخرون
منشور في: (2014)

Progress and challenges in TB vaccine development
حسب: Voss, G, وآخرون
منشور في: (2018)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
حسب: Pathan, A, وآخرون
منشور في: (2012)

NOW THE SOLUTION IS HERE – SOCIAL ASSISTANCE FOR ORPHANED CHILDREN: THE EXTENDED CHILD SUPPORT GRANT
حسب: Sipho Sibanda, وآخرون
منشور في: (2023-04-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
حسب: Pathan, A, وآخرون
منشور في: (2012)

A review of clinical models for the evaluation of human TB vaccines.
حسب: O'Shea, M, وآخرون
منشور في: (2016)

Advances in orphan drug development: Time to change the status and stereotype
حسب: Sayanta Thakur
منشور في: (2022-01-01)

Current status and trend of clinical development of orphan drugs in China
حسب: Ziling Xiang, وآخرون
منشور في: (2022-07-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
حسب: Morrell, L, وآخرون
منشور في: (2017)

Orphan drugs and rare diseases /
حسب: Pryde, David C., editor, وآخرون
منشور في: (2014)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
حسب: Kathryn T. Whelan, وآخرون
منشور في: (2011-01-01)

Donor investment choices in developing countries: a methodology and some illustrative results based on Public-Private partnerships for product development (PD PPPs)
حسب: Gray, A, وآخرون
منشور في: (2007)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
حسب: ZHANG Shan, وآخرون
منشور في: (2023-04-01)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
حسب: Odutola, A, وآخرون
منشور في: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
حسب: Odutola, A, وآخرون
منشور في: (2012)

Mechanism of coordinated access to orphan drugs
حسب: DeRidder R, وآخرون
منشور في: (2012-11-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
حسب: Eun Young Shin, وآخرون
منشور في: (2024-12-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
حسب: Liz Morrell, وآخرون
منشور في: (2017-08-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
حسب: Kathleen L. Miller, وآخرون
منشور في: (2020-09-01)

Rare diseases and orphan drugs.
حسب: Aronson, J
منشور في: (2006)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
حسب: McShane, H, وآخرون
منشور في: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
حسب: McShane, H, وآخرون
منشور في: (2014)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
حسب: Hans-Georg Eichler, وآخرون
منشور في: (2023-01-01)

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
حسب: Emma Rybalka, وآخرون
منشور في: (2023-05-01)

Financing drug discovery for orphan diseases
حسب: Gromatzky, Austin A., وآخرون
منشور في: (2014)

Sea Grant seeks new drugs from the sea
حسب: W Fenical
منشور في: (1997-07-01)

Sea Grant seeks new drugs from the sea
حسب: William Fenical
منشور في: (1997-07-01)

Status of orphan children in Ukraine in war
حسب: Andrukhiv O.
منشور في: (2022-06-01)